Adapt Pharma Announces Successful Completion of Intranasal Naloxone Study
April 22, 2015
Dublin, Ireland—April 22, 2015—Adapt Pharma Limited (“Adapt Pharma”) today announced the successful completion of a clinical study of naloxone nasal spray, a product currently under development. The pharmacokinetic study comparednaloxone nasal spray with an injectable formulation of naloxone.
The study met its objectives and demonstrated that the naloxone nasal spray formulation delivered the targeted naloxone dose as expected.
Naloxone is a Food and Drug Administration (FDA)-approved agent that treats the effects of opioid overdose caused by the use or misuse of prescription and illicit opioids.
Data from CDC WONDER, an information resource of the Centers for Disease Control and Prevention (CDC), indicate opioid overdose led to the loss of over 24,000 lives in America in 2013, a four‐fold increase since 1999. The majority of deaths occurred in a community setting (mostly at home), and approximately 70% were caused by prescription opioids.
Currently, all FDA‐approved formulations of naloxone are injectable products. Adapt is collaborating with the U.S. National Institute on Drug Abuse (NIDA) to develop a nasal spray naloxone dose and formulation that would be suitable for use in the community setting by nonmedically trained personnel.
About Adapt Pharma Limited
Adapt Pharma Limited is a privately held pharmaceutical company committed to making a positive impact on the lives of patients with specialty medical conditions. Adapt Pharma’s strategy is to identify, evaluate, selectively acquire, and enhance the value of late-stage development—and FDA-approved—pharmaceutical products. Adapt Pharma’s company headquarters is in Dublin, Ireland.